{"id":"gsk2140944-capsule","_chembl":null,"modality":"Small molecule","_dailymed":null,"mechanism":{"target":"Bacterial DNA gyrase and topoisomerase IV","explanation":"GSK2140944 is a bacterial type II topoisomerase inhibitor that blocks DNA replication in bacteria. Unlike fluoroquinolones, it has a novel binding mode that may overcome existing resistance mechanisms. It demonstrated activity against Gram-positive pathogens including drug-resistant strains.","oneSentence":"GSK2140944 inhibits bacterial DNA replication by targeting bacterial type II topoisomerases (DNA gyrase and topoisomerase IV)."},"_scrapedAt":"2026-03-28T02:39:57.439Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123884,"model":"claude-sonnet-4-5-20250929"},"competitors":[{"name":"linezolid","brand":"Zyvox","company":"Pfizer","rationale":"Oxazolidinone antibiotic for resistant Gram-positive infections"},{"name":"tedizolid","brand":"Sivextro","company":"Merck","rationale":"Next-generation oxazolidinone for ABSSSI"},{"name":"delafloxacin","brand":"Baxdela","company":"Melinta Therapeutics","rationale":"Fluoroquinolone for ABSSSI and pneumonia"}],"description":"GSK2140944 is an investigational antibiotic developed by GlaxoSmithKline that reached Phase 2 clinical trials for bacterial infections. It represents a novel class of antibacterial agents designed to address drug-resistant pathogens, though development appears to have been discontinued.","indications":{"approved":[{"status":"investigational","condition":"Acute bacterial skin and skin structure infections (ABSSSI)","patientPopulation":"Adult patients"},{"status":"investigational","condition":"Community-acquired bacterial pneumonia","patientPopulation":"Adult patients"}]},"trialDetails":[{"nctId":"NCT04187144","phase":"PHASE3","title":"Comparative Study to Evaluate Efficacy and Safety of Gepotidacin to Nitrofurantoin in Treatment of Uncomplicated Urinary Tract Infection (UTI)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2020-04-23","conditions":"Urinary Tract Infections","enrollment":1606},{"nctId":"NCT04020341","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Gepotidacin in the Treatment of Uncomplicated Urinary Tract Infection (UTI)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-10-17","conditions":"Urinary Tract Infections","enrollment":1531},{"nctId":"NCT04493931","phase":"PHASE1","title":"Drug-drug Interaction Study of Gepotidacin","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2020-08-14","conditions":"Infections, Bacterial","enrollment":64},{"nctId":"NCT02853435","phase":"PHASE1","title":"To Assess Bioavailability, Food Effect and Pharmacokinetics of Gepotidacin Tablets: A Phase I, Single-Dose, 2 Part Study in Healthy Subjects.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-08-04","conditions":"Infections, Bacterial","enrollment":48},{"nctId":"NCT02045797","phase":"PHASE2","title":"Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-03-24","conditions":"Infections, Bacterial","enrollment":126},{"nctId":"NCT02045849","phase":"PHASE1","title":"Relative Bioavailability, Safety, Tolerability, Pharmacokinetics (PK) and Food Effect Study of GSK2140944 in Healthy Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-01-28","conditions":"Infections, Bacterial","enrollment":46},{"nctId":"NCT02000765","phase":"PHASE1","title":"A Study to Investigate the Recovery, Excretion and Pharmacokinetics of [14C]-GSK2140944 Administered as a Single Intravenous and Single Oral Dose to Healthy Adult Male Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-11-08","conditions":"Infections, Respiratory Tract","enrollment":6},{"nctId":"NCT02294682","phase":"PHASE2","title":"A Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GSK2140944 in the Treatment of Uncomplicated Urogenital Gonorrhea Caused by Neisseria Gonorrhoeae","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-04-15","conditions":"Gonorrhea","enrollment":106},{"nctId":"NCT01706315","phase":"PHASE1","title":"This Study Will Investigate the Safety, Tolerability and Pharmacokinetic Profile of Repeat Oral Doses of GSK2140944 in Healthy Adult Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-10-17","conditions":"Infections, Respiratory Tract","enrollment":72}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"GSK2140944 capsule","genericName":"GSK2140944 capsule","companyName":"GlaxoSmithKline","companyId":"gsk","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}